Premium
Vascular endothelial growth factor: A potential target of therapy in neuromyelitis optica?
Author(s) -
Yamamura Takashi
Publication year - 2015
Publication title -
clinical and experimental neuroimmunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.297
H-Index - 15
ISSN - 1759-1961
DOI - 10.1111/cen3.12258
Subject(s) - neuromyelitis optica , medicine , vascular endothelial growth factor , bevacizumab , antibody , vegf receptors , immunology , chemotherapy
An open study was conducted to evaluate the safety of bevacizumab, anti‐vascular endothelial growth factor antibody, in patients with neuromyelitis optica developing signs of relapse.